How Did Lipitor's Patent Expiry Lower Drug Prices?
Lipitor (atorvastatin), Pfizer's blockbuster statin for cholesterol, had its main U.S. patent expire on November 30, 2011. This ended Pfizer's monopoly, allowing generic manufacturers like Ranbaxy, Watson, and Mylan to enter the market immediately. Within months, average wholesale prices dropped over 80%, from around $4 per pill to under $0.30 for generics.[1][2]
What Happened to Prices Right After Expiry?
Pre-expiry, a 30-day supply of brand-name Lipitor cost patients $150–$200 out-of-pocket, depending on insurance. Post-expiry in 2012, generic atorvastatin prices fell to $10–$20 for the same supply—a 90% reduction. By 2013, competition drove it below $5 monthly. This shift saved U.S. consumers and payers over $5 billion annually within two years.[1][3]
Why Did Prices Drop So Fast and Steeply?
Generic entry triggered immediate price competition. Pfizer's authorized generic (via Watson) accelerated the decline, undercutting its own brand. Multiple FDA approvals—over 15 generics by early 2012—flooded the supply, forcing prices down further. Studies show statins like Lipitor exemplify the "generic cliff," where 90%+ market share shifts to generics within a year, slashing costs.[2][4]
Did Everyone See Lower Costs Equally?
Insured patients benefited most through formularies favoring generics, often with $10 copays. Uninsured or high-deductible patients saved the most dramatically. However, some faced short-term hikes if stuck with brand-name via prior authorizations. Long-term, Medicare Part D spending on atorvastatin fell 92% by 2014.[3][5]
How Does Lipitor Compare to Other Blockbuster Patent Expiries?
Lipitor's drop mirrored patterns in drugs like Zocor (simvastatin, 2006 expiry: 85% price cut) and Plavix (2012: 80% drop), but steeper due to high volume (125 million prescriptions yearly). Unlike biologics with longer exclusivity, small-molecule generics like Lipitor clear the market faster, maximizing savings.[4]
Any Lingering Effects or Exceptions Today?
Generic atorvastatin now costs $2–$5 monthly, stable since 2015. Pfizer's later pediatric exclusivity (through 2016) delayed full entry slightly but didn't reverse gains. Ongoing patent challenges on formulations (e.g., chewables) have minimal impact on core tablet pricing.[6] DrugPatentWatch.com tracks remaining patents expiring in 2026+.
Sources:
[1] FDA Generic Competition and Drug Prices report (2017) - link
[2] IMS Health (now IQVIA) patent expiry analysis - link
[3] CMS Medicare Part D data (2011–2014) - link
[4] NBER study on generic entry effects - link
[5] HHS ASPE generic savings report - link
[6] DrugPatentWatch.com Lipitor patents